MSH4罕见错义变异与46,XX和46,XY个体原发性性腺衰竭相关
本研究对伊朗一个近亲家系进行全外显子组测序,该家系中多名男女成员患原发性性腺衰竭。发现原发性卵巢功能不全(POI)和非梗阻性无精子症(NOA)患者均为MSH4基因罕见错义变异p.S754L纯合子,少精子症患者为杂合子。该变异位于ATP酶结构域高度保守的MutS特征基序,预测有害,可能影响蛋白质构象和ATP酶活性。
要点
- MSH4 p.S754L纯合变异与POI和NOA相关,杂合见于少精子症。
- 变异位于ATP酶结构域MutS特征基序,预测有害并可能影响剪接。
- 对拟行TESE的NOA患者,排除减数分裂基因致病变异可能有帮助。
核心结论
- MSH4罕见错义变异p.S754L纯合与男女原发性性腺衰竭相关,杂合与少精子症相关。
研究设计与样本
- 回顾性遗传学研究,2018年在伊朗招募一个近亲家系,对先证者(POI)、NOA兄弟、可育姐妹及父母行全外显子组测序,其余家系成员Sanger验证。
主要发现
- POI和NOA患者为MSH4 p.S754L纯合,少精子症患者为杂合。
- 该变异在800名健康伊朗人及30例散发性NOA和30例散发性POI患者中未检出。
- 所有变异效应预测工具均提示该变异有害。
- 蛋白同源建模提示p.S754L可能引起构象变化,影响ATP酶活性。
关键数值与推荐
- 该变异在dbSNP编号rs377712900,已提交ClinVar(SCV001169709、SCV001169708、SCV001142647)。
临床怎么用
- 对男女不孕不育患者可考虑减数分裂基因变异检测以改善遗传咨询。
- NOA患者行睾丸精子提取(TESE)前,排除减数分裂基因致病变异可能有益。
局限性
- 变异效应基于预测工具和蛋白同源建模,需模型生物研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can whole-exome sequencing (WES) reveal a shared pathogenic variant responsible for primary gonadal failure in both male and female patients from a consanguineous family? SUMMARY ANSWER: Patients with primary ovarian insufficiency (POI) and non-obstructive azoospermia (NOA) were homozygous for the rare missense variant p. S754L located in the highly conserved MSH4 MutS signature motif of the ATPase domain. An oligozoospermic patient was heterozygous for the variant. WHAT IS KNOWN ALREADY: MSH4 is a meiosis-specific protein expressed at a certain level in the testes and ovaries. Along with its heterodimer partner MSH5, it is responsible for double-strand Holliday junction recognition and stabilization, to ensure accurate chromosome segregation during meiosis. Knockout male and female mice for Msh4 and Msh5 are reportedly infertile due to meiotic arrest. In humans, MSH4 is associated with male and female gonadal failure, with distinct variations in the MutS domain V. STUDY DESIGN, SIZE, DURATION: This was a retrospective genetics study of a consanguineous family with multiple cases of gonadal failure in both genders. The subject family was recruited in Iran, in 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: The proband who is affected by POI, an NOA brother, a fertile sister and their parents were subjected to WES. The discovered variant was validated in these individuals, and the rest of the family was also genotyped by Sanger sequencing. The variant was not detected in 800 healthy Iranian individuals from the Iranome database nor in 30 sporadic NOA and 30 sporadic POI patients. Suggested effect in aberrant splicing was studied by RT-PCR. Moreover, protein homology modeling was used to further investigate the amino acid substitution in silico. MAIN RESULTS AND THE ROLE OF CHANCE: The discovered variant is very rare and has never been reported in the homozygous state. It occurs in the ATPase domain at Serine 754, the first residue within the highly conserved MutS signature motif, substituting it with a Leucine. All variant effect prediction tools indicated this variant as deleterious. Since the substitution occurs immediately before the Walker B motif at position 755, further investigations based on protein homology were conducted. Considering the modeling results, the nature of the substituted amino acid residue and the distances between p. S754L variation and the residues of the Walker B motif suggested the possibility of conformational changes affecting the ATPase activity of the protein. LARGE SCALE DATA: We have submitted dbSNP entry rs377712900 to ClinVar under SCV001169709, SCV001169708 and SCV001142647 for oligozoospermia, NOA and POI, respectively. LIMITATIONS, REASONS FOR CAUTION: Studies in model organisms can shed more light on the role of this variant as our results were obtained by variant effect prediction tools and protein homology modeling. WIDER IMPLICATIONS OF THE FINDINGS: Identification of variants in meiotic genes should improve genetic counseling for both male and female infertility. Also, as two of our NOA patients underwent testicular sperm extraction (TESE) with no success, ruling out the existence of pathogenic variants in meiotic genes in such patients prior to TESE could prove useful. STUDY FUNDING/COMPETING INTEREST(S): This study was financially supported by Royan Institute in Tehran, Iran, and Institut Pasteur in Paris, France. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Akbari A, Padidar K, Salehi N, et al. Rare missense variant in MSH4 associated with primary gonadal failure in both 46, XX and 46, XY individuals. Hum Reprod. 2021. PMID: 33448284. doi:10.1093/humrep/deaa362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。